Ibrutinib CAS 936563-96-1 Tsaftace> 99.5% (HPLC) API

Ibrutinib (CAS: 936563-96-1) mai hanawa ne na Bruton tyrosine kinase (BTK) don maganin cutar sankarar lymphocytic na kullum (CLL) da lymphoma na mantle cell (MCL).Dukansu MCL da CLL suna cikin lymphoma na B-cell wanda ba Hodgkin ba, wanda ke da ƙarfi kuma yana da saurin dawowa.Ba a yi niyya da chemoimmunotherapy da aka saba amfani da shi ba, kuma mummunan halayen aji na 3 ko 4 yakan faru.Ibrutinib na iya haɗuwa tare da BTK, wanda ya zama dole don samuwar, bambance-bambance, sadarwa da kuma rayuwa na B lymphocytes, kuma ba tare da ɓata lokaci ba yana hana ayyukan BTK, yadda ya kamata ya hana yaduwar ƙwayoyin tumor.Bugu da ƙari, an shayar da shi da sauri bayan gudanarwa ta baki, matsakaicin matsakaicin ƙwayar plasma ya kai 1 ~ 2h, kuma mummunan halayen shine 1 ko 2, wanda zai zama sabon zaɓi don maganin CLL da MCL.A ranar 13 ga Nuwamba, 2013, FDA ta Amurka don haɓaka kamfanin Johnson & Johnson da aka amince da shi da Amurka Imbruvica (sunan gama gari: Ibrutinib) don kula da lymphoma cell cell (MCL).Ibrutinib, FDA ta ba shi matsayi na Farko a cikin Fabrairu 2013 kuma an amince da shi don MCL akan Nuwamba 13, 2013 da CLL akan Fabrairu 12, 2014, bi da bi.